Refine
Language
- English (31)
Has Fulltext
- yes (31)
Is part of the Bibliography
- no (31)
Keywords
- LHC (6)
- ALICE (3)
- ALICE experiment (2)
- pp collisions (2)
- 900 GeV (1)
- Beauty production (1)
- Cancer (1)
- Cancer genetics (1)
- Cancer genomics (1)
- Comparison with QCD (1)
- DTHR (1)
- Femtoscopy (1)
- Genomic instability (1)
- HBT (1)
- Hadron production (1)
- Heavy Ions (1)
- Heavy flavor production (1)
- Heavy flavour production (1)
- Heavy-ion collisions (1)
- Inclusive spectra (1)
- Intensity interferometry (1)
- Jets (1)
- Mid-rapidity (1)
- Molecular medicine (1)
- Multi-strange baryons (1)
- NETs (1)
- Neutrophils (1)
- Nuclear modification factor (1)
- PYTHIA (1)
- Pb–Pb (1)
- Proton–proton (1)
- ROS/RNS (1)
- Single electrons (1)
- Single muons (1)
- Transverse momentum (1)
- acute chronic inflammation (1)
- spectra (1)
- √sN N = 2.76 TeV (1)
Institute
- Physik (28)
- Frankfurt Institute for Advanced Studies (FIAS) (22)
- Informatik (22)
- Medizin (2)
- Georg-Speyer-Haus (1)
Chordomas are rare bone tumors with few therapeutic options. Here we show, using whole-exome and genome sequencing within a precision oncology program, that advanced chordomas (n = 11) may be characterized by genomic patterns indicative of defective homologous recombination (HR) DNA repair and alterations affecting HR-related genes, including, for example, deletions and pathogenic germline variants of BRCA2, NBN, and CHEK2. A mutational signature associated with HR deficiency was significantly enriched in 72.7% of samples and co-occurred with genomic instability. The poly(ADP-ribose) polymerase (PARP) inhibitor olaparib, which is preferentially toxic to HR-incompetent cells, led to prolonged clinical benefit in a patient with refractory chordoma, and whole-genome analysis at progression revealed a PARP1 p.T910A mutation predicted to disrupt the autoinhibitory PARP1 helical domain. These findings uncover a therapeutic opportunity in chordoma that warrants further exploration, and provide insight into the mechanisms underlying PARP inhibitor resistance.